CHO Plus Revenue and Competitors
Estimated Revenue & Valuation
- CHO Plus's estimated annual revenue is currently $2M per year.
- CHO Plus's estimated revenue per employee is $155,000
Employee Data
- CHO Plus has 13 Employees.
- CHO Plus grew their employee count by 8% last year.
CHO Plus's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder, CEO | Reveal Email/Phone |
2 | Chief Staff | Reveal Email/Phone |
3 | Chief Operating Officer | Reveal Email/Phone |
4 | VP and Head Protein Sciences | Reveal Email/Phone |
5 | Associate Director | Reveal Email/Phone |
CHO Plus Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is CHO Plus?
CHO Plus is creating regulatory compliant genetically engineered mammalian cells to be used by biopharmaceutical companies for therapeutic protein manufacturing. Early proof of concept experiments demonstrate CHO Plus cells to be 4.5-fold more productive than parent cells in model system. The CHO Plus approach includes patented methods for genetically engineering mammalian cells; proprietary and patented targeted transfection technology; and efficient clone screening technology.
keywords:N/A
N/A
Total Funding
13
Number of Employees
$2M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.4M | 13 | -19% | $109.9M |
#2 | $0.4M | 13 | 0% | $11.6M |
#3 | $0.6M | 13 | -13% | $96.4M |
#4 | $0.4M | 13 | 0% | $20.9M |
#5 | $1.1M | 13 | N/A | N/A |